Drug Trial Radar · NCT07552779
A Study of How Ibuzatrelvir is Taken up Into the Blood of Healthy Adults After Taking Different Tablets of Ibuzatrelvir
Last checked: Nov 20, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
17
Actual
Start
Apr 13, 2026
Primary completion
Jun 3, 2026
Study completion Jun 29, 2026
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Apr 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Healthy adults will be enrolled into this open-label, Phase 1 research study. Participants will spend about 9 nights and 10 days in the clinical research unit (CRU) and the total time in the study will be about 11 weeks. The goal of this clinical trial is to compare how much of the study drug ibuzatrelvir is in participants' blood after taking one of the two different types of tablets containing the same amount of ibuzatrelvir without food. The study will also measure how much ibuzatrelvir is in participants' blood after taking one type of the tablets dispersed in water and when one type of the tablets is taken with food. This study drug is taken by mouth.
Conditions
- Coronavirus Disease 2019
- Coronavirus Disease 2019 (COVID-19)
- COVID-19 (Coronavirus Disease 2019)
- Upper Respiratory Tract Infections
- Respiratory Tract Infection
- Respiratory Tract Diseases
- COVID-19
- COVID-19 Infection
- COVID-19 SARS-CoV-2 Infection
- Pneumonia
- Lung Diseases
Interventions
Ibuzatrelvir co-process API film coated tabletDrug
original
Ibuzatrelvir filmcoated tabletDrug
new
Primary outcomes
What the sponsor says the trial is designed to measure.
- Plasma ibuzatrelvir AUCinf (as data permit, otherwise AUClast) in the fasted stateTime frame: Hour 0 pre-dose in each period and 0.5, 1, 2, 4, 6, 8, 12, 24, and 48 post-dose in each period
- Plasma ibuzatrelvir AUCinf (as data permit, otherwise AUClast) in the fasted stateTime frame: Hour 0 pre-dose in each period and 0.5, 1, 2, 4, 6, 8, 12, 24, and 48 post-dose in each period
- Plasma ibuzatrelvir Cmax in the fasted stateTime frame: Hour 0 pre-dose in each period and 0.5, 1, 2, 4, 6, 8, 12, 24, and 48 post-dose in each period
- Plasma ibuzatrelvir Cmax in the fasted stateTime frame: Hour 0 pre-dose in each period and 0.5, 1, 2, 4, 6, 8, 12, 24, and 48 post-dose in each period
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pfizer Clinical Research Unit - Brussels
Brussels, Bruxelles-capitale, Région de, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.